-
公开(公告)号：US12220398B2
公开(公告)日：2025-02-11
申请号：US15750712
申请日：2016-08-18
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Kiyoshi Okamoto , Junji Matsui , Corina Dutcus
IPC: A61K31/357 , A61K31/47 , A61K31/664 , A61K31/675 , A61P35/00 , A61K31/7048
Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.
-
公开(公告)号：US20190000829A1
公开(公告)日：2019-01-03
申请号：US15748980
申请日：2016-08-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Junji Matsui , Masahiro Matsuki , Akihiko Tsuruoka , Toshiyuki Tamai , Ryo Nakajima , Takuya Suzuki
IPC: A61K31/47 , A61P35/00 , A61K31/095
Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.
-
公开(公告)号：US09527921B2
公开(公告)日：2016-12-27
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/32 , A61K33/24 , A61K31/47 , A61K31/337 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够生产包含重链和轻链的可变区以及小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
公开(公告)号：US10945990B2
公开(公告)日：2021-03-16
申请号：US15554540
申请日：2016-03-03
Applicant: MERCK SHARP & DOHME CORP. , Eisai R&D Management Co., Ltd.
Inventor： Junji Matsui , Gursel Aktan , Vassiliki Karantza , RuiRong Yuan , Yasuhiro Funahashi , Erhan Berrak
IPC: A61K31/357 , A61K45/06 , A61K39/395 , A61K9/00 , C07K16/28
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
-
公开(公告)号：US09969812B2
公开(公告)日：2018-05-15
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K14/705 , C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , C12N9/14 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
-
Patent Agency Ranking
公开(公告)号：US12029724B2
公开(公告)日：2024-07-09
申请号：US16090360
申请日：2017-04-26
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Makoto Asano , Junji Matsui
IPC: A61K31/357 , A61K9/127 , A61P35/00
CPC classification number: A61K31/357 , A61K9/127 , A61P35/00
Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20190111022A1
公开(公告)日：2019-04-18
申请号：US16090360
申请日：2017-04-26
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Makoto Asano , Junji Matsui
IPC: A61K31/357 , A61K9/127 , A61P35/00
Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
-
8.发明申请公开(公告)号：US20180209980A1
公开(公告)日：2018-07-26
申请号：US15934242
申请日：2018-03-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki , Junji Matsui , Jason S. Simon , Lucy Xu
IPC: G01N33/574 , C12Q1/6886 , A61K31/47
CPC classification number: G01N33/57407 , A61K31/47 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57438
Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
-
公开(公告)号：US20160347858A1
公开(公告)日：2016-12-01
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了所述小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够产生包含重链和轻链的可变区以及所述小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
公开(公告)号：US20140148483A1
公开(公告)日：2014-05-29
申请号：US14117276
申请日：2012-05-16
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
CPC classification number: C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
Abstract translation: 本发明的目的是提供一种用于预测患有肿瘤的受试者中血管生成抑制剂的有效性的方法。 提供了一种方法，其包括测试来自受试者的肿瘤组织样品中是否存在B-Raf和PTEN的突变或丧失的表达的存在或不存在的步骤。 通过使用B-Raf和PTEN的表达的存在或不存在或突变或丧失作为指标，该方法能够预测血管生成抑制剂的抗肿瘤效力，而不向受试者施用血管生成抑制剂。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.025 seconds)
